NASDAQ: SEERSeer Inc Stock
$1.93-0.03 (-1.53%)
Updated Apr 29, 2025
SEER Price
$1.93
Fair Value Price
N/A
Market Cap
$115.38M
52 Week Low
$1.56
52 Week High
$2.63
P/E
-1.39x
P/B
0.35x
P/S
10.16x
PEG
N/A
Dividend Yield
N/A
Revenue
$14.17M
Earnings
-$86.60M
Gross Margin
49.8%
Operating Margin
-610.45%
Profit Margin
-611.1%
Debt to Equity
0.12
Operating Cash Flow
-$46M
Beta
1.84
Next Earnings
Jun 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SEER Overview
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SEER's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SEER
Ranked#117 of 462
Ranked#117 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.96 | A | |
| $8.12 | A | |
| $24.28 | A |
Be the first to know about important SEER news, forecast changes, insider trades & much more!
SEER News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SEER scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SEER is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SEER is good value based on its book value relative to its share price (0.35x), compared to the US Biotechnology industry average (4.37x)
P/B vs Industry Valuation
SEER is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SEER due diligence checks available for Premium users.
Valuation
SEER price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.39x
Industry
-158.75x
Market
29.19x
SEER price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.35x
Industry
4.37x
SEER is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SEER's financial health
Profit margin
Revenue
$4.0M
Net Income
-$21.7M
Profit Margin
-543.6%
SEER's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SEER's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$366.6M
Liabilities
$39.0M
Debt to equity
0.12
SEER's short-term assets ($253.32M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SEER's short-term assets ($253.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SEER's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SEER's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$11.5M
Investing
$15.8M
Financing
-$1.3M
SEER's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SEER vs Biotech Stocks
Seer Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.